Pembrolizumab相关论文
目的:通过meta分析评估细胞程序性死亡受体1（programmed cell death protein-1,PD-1）/细胞程序性死亡-配体1（programmed cell death l......
Effectiveness and Safety of PD-1 Inhibitors in the Treatment against Solid Tumors: A Systematic Revi
目的 PD-1/PD-L1 inhibitors have been implicated as potentially effective anti-cancer therapies. Some clinical Randomized......
Safety Data From KEYNOTE-059 Cohort 2: Pembrolizumab Plus 5-Fluorouracil (5-FU) and Cisplatin for Fi
...
Patients with metastatic renal cell carcinoma treated with axitinib combined with low dose pembroliz
Background: Although sunitinib is approved treatments in first-line therapy for patients with metastatic renal cell carc......
...
Recurrent undifferentiated embryonal sarcoma of the liver in adult patient treated by pembrolizumab:
BACKGROUND Undifferentiated embryonal sarcoma of the liver(UESL)is a neoplasm that rarely develops in adults.The main tr......
【目的】乳腺癌是女性发病率最高的恶性肿瘤,其中三阴型乳腺癌(triple negative breast cancer,TNBC)是恶性程度最高的亚型之一,且......
,Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliar
Background: A therapeutic strategy involving combined treatment with lenvatinib plus pembrolizumab (LEP) has demonstrate......
On May 23,2017,the US Food and Drug Administration (FDA) approved a treatment for cancer patients with positive microsat......
1 文献来源rnPaz ? Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non?small?cell lung can......
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7......
Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor:A c
BACKGROUND Thymic epithelial carcinomas are rare and have a poor prognosis.Treatment of thymic epithelial carcinoma is m......
文献来源文献一:AndréT,Shiu KK,Kim TW,et al.Pembrolizumab in microsatellite⁃instability⁃high advanced colorectal c......
1文献来源Le D T,Kim T W,Van Cutsem E,et al.PhaseⅡopen⁃label study of pembrolizumab in treatment⁃refractory,microsatel......
Background:Immunity plays a major role in carcinogenesis and this is the case also for hepatocellular carcinomas(HCC).Ch......
目的:了解帕博利珠单抗致免疫相关性心肌炎发生的规律和特点,为临床合理用药提供参考。方法:以"帕博利珠单抗/可瑞达"和"心肌炎""......
目的:系统评价PD-1抑制剂对比化疗治疗进展期黑色素瘤的有效性和安全性。方法:计算机检索PubMed、EMbase、CNKI、VIP、Wanfang Dat......
包括血管生长因子受体（vascular endothelial growth factor receptor,VEGFR）抑制剂在内的多种分子靶向药物在过去的10年内极大地改......
1文献来源Rudin CM,Awad MM,Navarro A,et al.Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for......
肺癌是我国发病率和死亡率最高的恶性肿瘤,2015年我国新发和死亡肺癌病例分别为733 300和610 200例[1],并且发病率仍有升高趋势。......
期刊
Prognostic and Predictive Value of Pretreatment Derived Neutrophil-to-Lymphocyte Ratio in Non-Small-
Background: Immune checkpoint inhibitors produce prolonged responses in select non-small cell lung cancer (NSCLC) patien......
目的观察程序性死亡受体1(PD-1)单克隆抗体(单抗)Pembrolizumab治疗晚期肺癌的疗效和毒副反应。方法28例晚期肺癌患者,均接受PD-1......
背景和目的:近年来,免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)已成为最有前景的抗癌药物之一,其疗效已在一系列临床试......
目的:免疫检查点抑制剂(Immune checkpoint inhibitors,ICIs)是近年来肿瘤治疗领域的一个热点。ICIs治疗显著延长了恶性肿瘤患者的......
<正>2018年10月,默沙东公司宣布,美国FDA批准该公司的pembrolizumab(Keytruda)与卡铂和紫杉醇联用,作为一线疗法治疗转移性鳞状细......
1 病历摘要患者女,43岁,2016-05-16因"腰痛2月余,发现左侧头皮下肿物1月余"于外院就诊,CT提示:①左肺下叶周围型肺癌并C6~7、T2及T......
期刊
BACKGROUND Pembrolizumab is an anti-programmed death receptor 1(PD-1)that was shown to have a tolerable safety profile w......
1文献来源Paz-Ares L,Luft A,Vicente D,et al.Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J].N ......
目的探讨PD-1抑制剂Pembrolizumab联合培美曲塞治疗非小细胞肺癌的疗效及对术后患者CYFRA21-1、CEA及CA125水平的影响。方法选取笔......
1文献来源Herbst RS,Baas P,Kim DW,et al.Pembrolizumab versus Docetaxel for previouslytreated,PD-L1-positive,advanced non-......
万众瞩目的2项PD-1免疫检查点抑制剂进军非小细胞肺癌一线治疗（Keynote024和Checkmate026）的临床数据在本届ESMO大会上公布，尽管早在2......
1文献来源Rizvi NA,Hellmann MD,Snyder A,et al.Mutational landscape determines sensitivity to PD-1blockade in non-small ce......
目的靶向程序性死亡分子1(programmed cell death ligand 1,PD-1)通路的肿瘤免疫治疗在多种类型肿瘤中取得了卓越的临床疗效,包括......
3背景三阴性乳腺癌（triple negative breast cancer，TNBC）即激素受体（hormone receptor，HR）阴性、人表皮生长因子受体2（humanepid ermal r......
BACKGROUND Few studies have addressed the efficacy of pembrolizumab in pulmonary sarcomatoid carcinoma(PSC),a rare,previ......
<正>美国FDA于2014年9月4日采用"加速批准"(accelerated approval)的方式批准Keytruda(pembrolizumab)用于治疗对其他药物无反应的......
BACKGROUND Programmed cell death-1(PD-1)inhibitor has been indicated for many types of malignancies.However,these inhibi......
ue＊M＃’＃dkB4＃＃8＃”专利申请号:00109“7公开号:1278062申请日:00.06.23公开日:00.12.27申请人地址:（100084川C京市海淀区清华园申请人:清......
研究背景肺癌目前是我国发病率和致死率最高的恶性肿瘤,其中大约85%为非小细胞肺癌(non-small cell lung cancer,NSCLC)。2013 年,......
Pembrolizumab是一种结合于程序性死亡受体-1(PD-1)的单克隆抗体,通过阻断PD-1和PD-L1及PD-L2间的相互作用,从而阻断PD-1通路介导......
<正>在控制肿瘤细胞的生长、扩散和复发过程中,T细胞介导的免疫应答有着重要的作用。T细胞的活化需要双信号作用,第一信号来自抗原......
<正>1文献来源Langer CJ,Gadgeel SM,Borghaei H,et al.Carboplatin and Pemetrexed with or without Pembrolizumab for advanced......
<正>1文献来源Reck M,Rodríguez-Abreu D,Robinson AG,etal.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-c......
以PD-1/PD-L1单抗为代表的免疫检查点抑制剂是近年来肿瘤免疫治疗的热点。PD-L1在胃癌中的表达相较正常组织明显上调,但其表达水平......
程序性死亡生长因子-1(PD-1/CD279)是新近研究的热门分子,PD-1与其配体PD-L1/2(B7-H1/CD274)最终导致淋巴细胞"耗尽"以及诱导免疫......
<正>非小细胞肺癌(non-small cell lung cancer,NSCLC)占肺癌的80%~90%[1]。以铂类药物为主的化疗仅对的30%的NSCLC患者有效[2],还......
背景NK/T细胞淋巴瘤（Natural Killer T-Cell Lymphoma,NKTCL）是非霍奇金淋巴瘤的一个亚型,在中国的发病率远高于西方国家。NKTCL是一......
程序性死亡受体-1（PD-1）抑制剂Pembrolizumab通过阻断PD-1与其配体PD-L1结合，阻断负向调控信号通路，恢复T细胞的功能活性，增强机体的抗......
免疫检查点抑制剂在中国获批时间较短,真实世界的临床数据尚处于收集阶段,国内程序细胞死亡蛋白1(programmed death-1,PD-1)治疗相......
期刊
